Skip to main content
Top
Published in: Infectious Diseases and Therapy 1/2021

Open Access 01-03-2021 | Vaccination | Original Research

Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data

Authors: Heather L. Sings, Bradford D. Gessner, Matt D. Wasserman, Luis Jodar

Published in: Infectious Diseases and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

Limited changes in serotype 3 invasive pneumococcal disease (IPD) incidence rates after a decade of 13-valent pneumococcal conjugate vaccine (PCV13) introduction into several national immunization programs (NIP) have raised questions about PCV13's effectiveness against this serotype.

Methods

We analyzed the impact of pediatric PCV programs on serotype 3 IPD with two approaches. First, we reviewed the publicly available surveillance data from countries identified in two recently published reviews to describe the population impact of pediatric PCV13 or PCV10 vaccination programs on serotype 3 IPD. We then compared the observed trends in PCV10 and PCV13 countries to a previously described dynamic transmission model that simulates the spread of pneumococcal carriage and development of IPD in a population over time.

Results

When serotype 3 disease rates are compared from countries that have introduced either a 10-valent (PCV10) vaccine that does not contain serotype 3 in its formulation or PCV13 in their pediatric NIP, over time, serotype 3 incidence rate trends are markedly different. Countries with a PCV10 NIP showed a substantial linear increase in serotype 3 pneumococcal disease among all age groups since the time of PCV10 introduction, whereas countries with a PCV13 NIP experienced a modest decline during the 3–4 years after vaccine introduction followed by an inflection upward in subsequent years.

Conclusion

These data suggest that PCV13 provides a certain degree of direct and indirect protection against serotype 3 at the population level and direct adult vaccination with a serotype 3-containing vaccine is likely to provide substantial benefit in the context of a pediatric PCV NIP. Further research around serotype 3 transmission patterns and epidemiology is nonetheless warranted.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sings HL. Pneumococcal conjugate vaccine use in adults—addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017;35(40):5406–17.CrossRef Sings HL. Pneumococcal conjugate vaccine use in adults—addressing an unmet medical need for non-bacteremic pneumococcal pneumonia. Vaccine. 2017;35(40):5406–17.CrossRef
2.
go back to reference Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135–43.CrossRef Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135–43.CrossRef
3.
go back to reference Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Eng J Med. 2015;372:1114–25.CrossRef Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Eng J Med. 2015;372:1114–25.CrossRef
4.
go back to reference Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019;37(30):4147–54.CrossRef Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019;37(30):4147–54.CrossRef
5.
go back to reference McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6.CrossRef McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6.CrossRef
6.
go back to reference Warren JL, Weinberger DM. Estimating serotype-specific efficacy of pneumococcal conjugate vaccines using hierarchical models. Epidemiology. 2020;31(2):259–62.CrossRef Warren JL, Weinberger DM. Estimating serotype-specific efficacy of pneumococcal conjugate vaccines using hierarchical models. Epidemiology. 2020;31(2):259–62.CrossRef
8.
go back to reference Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51.CrossRef Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51.CrossRef
9.
go back to reference Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57(7):952–62.CrossRef Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57(7):952–62.CrossRef
10.
go back to reference Hanquet G, Krizova P, Valentiner-Branth P, on behalf of The SpIDnet/I-MOVE+ Pneumo Group, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473–82.CrossRef Hanquet G, Krizova P, Valentiner-Branth P, on behalf of The SpIDnet/I-MOVE+ Pneumo Group, et al. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. Thorax. 2019;74(5):473–82.CrossRef
11.
go back to reference Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: Assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93.CrossRef Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: Assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93.CrossRef
12.
go back to reference Wasserman M, Lucas A, Jones D, et al. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018;146(14):1797–806.CrossRef Wasserman M, Lucas A, Jones D, et al. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018;146(14):1797–806.CrossRef
13.
go back to reference Lucas A, Wilson M, Sings HL, et al. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. Int J Infect Dis Ther. 2019;4(4):56–66. Lucas A, Wilson M, Sings HL, et al. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. Int J Infect Dis Ther. 2019;4(4):56–66.
16.
go back to reference Pilishvili T, Advisory Committee on Immunization Practices. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3 [Analysis in brief on the Internet]. 2019 Feb 28. Available at https://www.cdc.gov/vaccines/acip/meetings/slides-2019-02.html/. Accessed 16 June 2019. Note that requests for slide presentation files prior to the ones currently posted on their website may be sent to acip@cdc.gov. Pilishvili T, Advisory Committee on Immunization Practices. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3 [Analysis in brief on the Internet]. 2019 Feb 28. Available at https://​www.​cdc.​gov/​vaccines/​acip/​meetings/​slides-2019-02.​html/​. Accessed 16 June 2019. Note that requests for slide presentation files prior to the ones currently posted on their website may be sent to acip@cdc.gov.
17.
go back to reference Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.CrossRef Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.CrossRef
18.
go back to reference Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–9.CrossRef Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–9.CrossRef
20.
go back to reference Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–67.CrossRef Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–67.CrossRef
21.
go back to reference Siegel SJ, Weiser JN. Mechanisms of bacterial colonization of the respiratory tract. Annu Rev Microbiol. 2015;69:425–44.CrossRef Siegel SJ, Weiser JN. Mechanisms of bacterial colonization of the respiratory tract. Annu Rev Microbiol. 2015;69:425–44.CrossRef
22.
go back to reference Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185(7):927–36.CrossRef Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185(7):927–36.CrossRef
23.
go back to reference Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192(7):853–8.CrossRef Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192(7):853–8.CrossRef
24.
go back to reference German EL, Solorzano C, Sunny S, et al. Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonization density. Vaccine. 2019;37(30):3953–6.CrossRef German EL, Solorzano C, Sunny S, et al. Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonization density. Vaccine. 2019;37(30):3953–6.CrossRef
25.
go back to reference Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46.CrossRef Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46.CrossRef
26.
go back to reference Pennington SH, Pojar S, Mitsi E, et al. Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage. Am J Respir Crit Care Med. 2016;194(12):1523–31.CrossRef Pennington SH, Pojar S, Mitsi E, et al. Polysaccharide-specific memory B cells predict protection against experimental human pneumococcal carriage. Am J Respir Crit Care Med. 2016;194(12):1523–31.CrossRef
27.
go back to reference Azarian T, Mitchell P, Georgieva M, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog. 2018;14(11):e11007438.CrossRef Azarian T, Mitchell P, Georgieva M, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog. 2018;14(11):e11007438.CrossRef
28.
go back to reference Groves N, Sheppard CL, Litt D, et al. Evolution of streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader. Genes (Basel). 2019;10(11):845.CrossRef Groves N, Sheppard CL, Litt D, et al. Evolution of streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader. Genes (Basel). 2019;10(11):845.CrossRef
29.
go back to reference von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371:1889–99.CrossRef von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371:1889–99.CrossRef
37.
go back to reference Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015;33(Suppl 4):D60–5.CrossRef Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015;33(Suppl 4):D60–5.CrossRef
Metadata
Title
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Authors
Heather L. Sings
Bradford D. Gessner
Matt D. Wasserman
Luis Jodar
Publication date
01-03-2021
Publisher
Springer Healthcare
Keyword
Vaccination
Published in
Infectious Diseases and Therapy / Issue 1/2021
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-021-00406-w

Other articles of this Issue 1/2021

Infectious Diseases and Therapy 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.